Dr. Lior Shaltiel reports

NUREXONE REPORTS NEW PRECLINICAL TISSUE-ANALYSIS DATA SUPPORTING POTENTIAL NEUROPROTECTIVE EFFECT OF EXOPTEN IN ACUTE SPINAL CORD INJURY ANIMAL MODEL

Nurexone Biologic Inc. has released new preclinical tissue-analysis results that provide additional biological support for ExoPTEN's potential neuroprotective effect in an animal model of traumatic spinal cord injury.

The findings provide an important new biological dimension to the ExoPTEN's efficacy profile.

Nurexone has previously reported improved functional recovery in animals treated with ExoPTEN (press release dated July 8, 2025). In the current analysis, spinal cord tissue collected from those same animals and evaluated to assess biological markers associated with neurons and supporting structures. Two months after injury, ExoPTEN-treated animals showed significantly higher numbers of cells positive for myelin basic protein (MBP), a key component of the protective coating surrounding nerve fibres, compared with controls in regions on both sides of the injury site.

These data further inform Nurexone's understanding of ExoPTEN's potential mechanism of action and contribute to the scientific and regulatory foundation supporting the program as it advances through preclinical development toward potential clinical development.

"These results are important as we continue to gain biological rationale behind the functional recovery observed previously in ExoPTEN-treated animals," said Dr. Tali Kizhner, director of research and development at Nurexone. "Nerve cells depend on a protective coating, much like electrical wires depend on insulation, to carry signals. Two months after injury, ExoPTEN-treated animals had significantly higher numbers of MBP-positive cells on both sides of the injury site compared with controls. These findings provide additional preclinical evidence supporting ExoPTEN's potential neuroprotective effect and may help us better understand how ExoPTEN could support neural tissue preservation and recovery following injury."

Analyzing the biology of functional recovery

Acute spinal cord injuries can trigger a cascade of biological processes beyond the initial trauma that can contribute to further damage to nerve cells and their supporting structures. Protecting surviving neural tissue and the structures needed for nerve signalling is therefore an important therapeutic objective.

To study ExoPTEN's mechanism of action within the injured spinal cord, the company performed a broad immunohistochemical analysis using target tissues collected from a previously reported efficacy study. Three areas of the spinal cord were assessed independently: the injury area itself and regions rostral (toward the head) and caudal (toward the tail) to the injury site.

Researchers examined several markers associated with neurons and their supporting structures:

• NeuN, a marker associated with neuronal nuclei and cell bodies;
• NF200, a marker of neuronal axons and cell bodies;
• MBP, a major component of myelin and a marker used to identify the myelin sheaths that insulate nerve fibre.

Two months after spinal cord injury, ExoPTEN-treated animals showed significantly higher numbers of MBP-positive cells compared with controls in regions on both sides of the injury. The differences were statistically significant in both the rostral region (p equals 0.01) and caudal region (p equals 0.04).

These findings provide additional preclinical evidence supporting ExoPTEN's potential neuroprotective effect and may help biologically explain the functional improvement previously observed in treated animals.

About ExoPTEN

ExoPTEN is Nurexone's lead exosome-based therapeutic candidate for acute spinal cord injury. ExoPTEN uses bone marrow-derived naive exosomes loaded with proprietary siRNA targeting PTEN and is being developed as a minimally invasive therapeutic approach intended to promote recovery following nerve injury.

Investor awareness engagement with BullVestor

The company has entered into an advertising and investor awareness agreement with BullVestor Medien GmbH, an arm's-length party to the company based in Austria, pursuant to which BullVestor will provide advertising, communications and investor awareness services in Austria, Germany and Switzerland. The agreement commences on Aug. 10, 2026, and will run on a flexible month-to-month basis, terminable by the company at the end of the then-current billing month; however, BullVestor will not commence providing any investor relations, promotional, investor awareness, advertising, marketing, distribution, media placement, digital media, direct marketing, database management, investor communications, social media, targeted advertising, retargeting, lead generation or related services unless, and until the agreement has been accepted by the TSX Venture Exchange, if such acceptance is required. BullVestor will be paid $2,500 per month for the monthly awareness program and, if the company elects to proceed with optional additional awareness campaigns, additional consideration of up to $480,000 in the aggregate based on individual campaigns ranging from $20,000 to $60,000 per campaign. No optional additional awareness campaign will be commenced, and no additional fees will become payable, unless the company has approved in writing the final scope, pricing, timing, channels, deliverables and campaign materials for such campaign, and the company has obtained any required prior acceptance of the TSX Venture Exchange. The consideration payable to BullVestor is payable solely in cash and does not include any securities of the company. To the knowledge of the company, BullVestor does not have any interest, directly or indirectly, in the securities of the company, or any right or intent to acquire such an interest. The engagement remains subject to the acceptance of the TSX-V.

About Nurexone Biologic Inc.

Nurexone is a TSX-V-, OTCQB- and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the orphan drug designation, facilitate the company's road map toward clinical trials in the United States and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top to anchor its North American activity and growth strategy.

We seek Safe Harbor.